GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
GeneTether Therapeutics Inc. has announced its third-quarter financial results and a strategic move to license the STS-201 drug development program, which could unlock significant value for shareholders. The company’s financials reveal a stable cash position with a minor quarterly loss, while it plans a private placement to support the new drug initiative. Both the licensing and private placement are pending shareholder approval at an upcoming meeting.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.
